Geoffrey Porges
Stock Analyst at SVB Leerink
(1.36)
# 3,334
Out of 4,735 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.64 | +110.21% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $13.56 | +47.49% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $14.14 | +607.21% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $687.80 | +23.58% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $55.94 | -14.19% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $274.81 | -21.40% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $172.61 | -21.79% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.27 | -2.40% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $92.96 | -19.32% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $51.69 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.15 | +9.29% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.53 | +5,559.31% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $427.89 | -59.10% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $14.30 | +487.41% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.78 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $4.41 | +648.30% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $11.10 | +449.55% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $140.98 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.64
Upside: +110.21%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $13.56
Upside: +47.49%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $14.14
Upside: +607.21%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $687.80
Upside: +23.58%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $55.94
Upside: -14.19%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $274.81
Upside: -21.40%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $172.61
Upside: -21.79%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.27
Upside: -2.40%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $92.96
Upside: -19.32%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $51.69
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.15
Upside: +9.29%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.53
Upside: +5,559.31%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $427.89
Upside: -59.10%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $14.30
Upside: +487.41%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $33.78
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $4.41
Upside: +648.30%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $11.10
Upside: +449.55%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $140.98
Upside: -